Modern management of malignant pleural mesothelioma

Shivani C. Patel, Jonathan E. Dowell

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Malignant pleural mesothelioma (MPM) is a deadly disease that produces a significant worldwide health care burden. The majority of cases are associated with prior asbestos exposure, but recent studies have identified a possible genetic predisposition in a minority of patients. Historically, obtaining a pathologic diagnosis of MPM was challenging, but with current pathological techniques, a secure diagnosis is possible in the majority of patients. Curative therapy for MPM remains elusive, and the primary treatment option for fit patients is platinum-based chemotherapy. Encouraging recent reports suggest that there may be a benefit to the addition of bevacizumab to standard chemotherapy as well as with the use of immune checkpoint inhibitors in MPM. Selected patients may be considered for aggressive surgical approaches, but there is considerable controversy regarding the true benefit of surgery and multimodality therapy in this disease.

Original languageEnglish (US)
Pages (from-to)63-72
Number of pages10
JournalLung Cancer: Targets and Therapy
Volume7
DOIs
StatePublished - May 3 2016

Fingerprint

Drug Therapy
Asbestos
Genetic Predisposition to Disease
Platinum
Therapeutics
Delivery of Health Care
Malignant Mesothelioma
Global Health
Bevacizumab

Keywords

  • Asbestos
  • Chemotherapy
  • Mesothelioma
  • Surgery

ASJC Scopus subject areas

  • Oncology

Cite this

Modern management of malignant pleural mesothelioma. / Patel, Shivani C.; Dowell, Jonathan E.

In: Lung Cancer: Targets and Therapy, Vol. 7, 03.05.2016, p. 63-72.

Research output: Contribution to journalReview article

@article{9de065fca0e64961b4718ecfb865d7ba,
title = "Modern management of malignant pleural mesothelioma",
abstract = "Malignant pleural mesothelioma (MPM) is a deadly disease that produces a significant worldwide health care burden. The majority of cases are associated with prior asbestos exposure, but recent studies have identified a possible genetic predisposition in a minority of patients. Historically, obtaining a pathologic diagnosis of MPM was challenging, but with current pathological techniques, a secure diagnosis is possible in the majority of patients. Curative therapy for MPM remains elusive, and the primary treatment option for fit patients is platinum-based chemotherapy. Encouraging recent reports suggest that there may be a benefit to the addition of bevacizumab to standard chemotherapy as well as with the use of immune checkpoint inhibitors in MPM. Selected patients may be considered for aggressive surgical approaches, but there is considerable controversy regarding the true benefit of surgery and multimodality therapy in this disease.",
keywords = "Asbestos, Chemotherapy, Mesothelioma, Surgery",
author = "Patel, {Shivani C.} and Dowell, {Jonathan E.}",
year = "2016",
month = "5",
day = "3",
doi = "10.2147/LCTT.S83338",
language = "English (US)",
volume = "7",
pages = "63--72",
journal = "Lung Cancer: Targets and Therapy",
issn = "1179-2728",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Modern management of malignant pleural mesothelioma

AU - Patel, Shivani C.

AU - Dowell, Jonathan E.

PY - 2016/5/3

Y1 - 2016/5/3

N2 - Malignant pleural mesothelioma (MPM) is a deadly disease that produces a significant worldwide health care burden. The majority of cases are associated with prior asbestos exposure, but recent studies have identified a possible genetic predisposition in a minority of patients. Historically, obtaining a pathologic diagnosis of MPM was challenging, but with current pathological techniques, a secure diagnosis is possible in the majority of patients. Curative therapy for MPM remains elusive, and the primary treatment option for fit patients is platinum-based chemotherapy. Encouraging recent reports suggest that there may be a benefit to the addition of bevacizumab to standard chemotherapy as well as with the use of immune checkpoint inhibitors in MPM. Selected patients may be considered for aggressive surgical approaches, but there is considerable controversy regarding the true benefit of surgery and multimodality therapy in this disease.

AB - Malignant pleural mesothelioma (MPM) is a deadly disease that produces a significant worldwide health care burden. The majority of cases are associated with prior asbestos exposure, but recent studies have identified a possible genetic predisposition in a minority of patients. Historically, obtaining a pathologic diagnosis of MPM was challenging, but with current pathological techniques, a secure diagnosis is possible in the majority of patients. Curative therapy for MPM remains elusive, and the primary treatment option for fit patients is platinum-based chemotherapy. Encouraging recent reports suggest that there may be a benefit to the addition of bevacizumab to standard chemotherapy as well as with the use of immune checkpoint inhibitors in MPM. Selected patients may be considered for aggressive surgical approaches, but there is considerable controversy regarding the true benefit of surgery and multimodality therapy in this disease.

KW - Asbestos

KW - Chemotherapy

KW - Mesothelioma

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84975270786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975270786&partnerID=8YFLogxK

U2 - 10.2147/LCTT.S83338

DO - 10.2147/LCTT.S83338

M3 - Review article

VL - 7

SP - 63

EP - 72

JO - Lung Cancer: Targets and Therapy

JF - Lung Cancer: Targets and Therapy

SN - 1179-2728

ER -